DNA‐binding assays confirmed the direct binding of STAT3 to the Bcl‐XL promoter in primary CLL cells and showed that JAK–STAT signalling did not compete or interfere with the binding of NF‐κB to the Bcl‐XL promoter. Here, STAT3 is linked to B-cell chronic lymphocytic leukemia.